Impact of pancreas transection site on incidence of pancreatic fistula after distal pancreatectomy: a propensity score matched study.


Journal

HPB : the official journal of the International Hepato Pancreato Biliary Association
ISSN: 1477-2574
Titre abrégé: HPB (Oxford)
Pays: England
ID NLM: 100900921

Informations de publication

Date de publication:
23 May 2024
Historique:
received: 23 12 2023
revised: 24 04 2024
accepted: 20 05 2024
medline: 6 6 2024
pubmed: 6 6 2024
entrez: 5 6 2024
Statut: aheadofprint

Résumé

Distal pancreatectomy (DP) is performed for lesions in the body and tail of the pancreas. The morbidity profile is considerable, mainly due to clinically relevant postoperative pancreatic fistula (CR-POPF). This study aims to investigate potential differences in CR-POPF related to transection site. An observational cohort study from a prospectively maintained database was performed. Subtotal distal pancreatectomy (SDP) was defined as transection over the superior mesenteric vein, and DP was defined as transection lateral to this point. Propensity score matching (PSM) in 1:1 fashion was applied based on demographical and perioperative variables. Six hundred and six patients were included in the analysis (1997-2020). Four hundred twenty (69.3%) underwent DP, while 186 (30.7%) underwent SDP. The rate of CR-POPF was 19.3% after DP and 20.4% after SDP (p = 0.74). SDP was associated with older age (63.1 vs 60.1 years, p = 0.016), higher occurrence of ductal adenocarcinoma (37.1 vs 17.6%, p = 0.001) and more frequent use of neoadjuvant chemotherapy (3.8 vs 0.7%, p = 0.012). After PSM, 155 patients were left in each group. The difference in CR-POPF between DP and SDP remained statistically non-significant (20.6 vs 18.7%, p = 0.67). This study found no difference in CR-POPF related to transection site during distal pancreatectomy.

Sections du résumé

BACKGROUND BACKGROUND
Distal pancreatectomy (DP) is performed for lesions in the body and tail of the pancreas. The morbidity profile is considerable, mainly due to clinically relevant postoperative pancreatic fistula (CR-POPF). This study aims to investigate potential differences in CR-POPF related to transection site.
METHODS METHODS
An observational cohort study from a prospectively maintained database was performed. Subtotal distal pancreatectomy (SDP) was defined as transection over the superior mesenteric vein, and DP was defined as transection lateral to this point. Propensity score matching (PSM) in 1:1 fashion was applied based on demographical and perioperative variables.
RESULTS RESULTS
Six hundred and six patients were included in the analysis (1997-2020). Four hundred twenty (69.3%) underwent DP, while 186 (30.7%) underwent SDP. The rate of CR-POPF was 19.3% after DP and 20.4% after SDP (p = 0.74). SDP was associated with older age (63.1 vs 60.1 years, p = 0.016), higher occurrence of ductal adenocarcinoma (37.1 vs 17.6%, p = 0.001) and more frequent use of neoadjuvant chemotherapy (3.8 vs 0.7%, p = 0.012). After PSM, 155 patients were left in each group. The difference in CR-POPF between DP and SDP remained statistically non-significant (20.6 vs 18.7%, p = 0.67).
CONCLUSION CONCLUSIONS
This study found no difference in CR-POPF related to transection site during distal pancreatectomy.

Identifiants

pubmed: 38839509
pii: S1365-182X(24)01738-6
doi: 10.1016/j.hpb.2024.05.012
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

Copyright © 2024 The Author(s). Published by Elsevier Ltd.. All rights reserved.

Auteurs

Trond Kjeseth (T)

Department of HPB Surgery, Oslo University Hospital, Rikshospitalet, Oslo, Norway. Electronic address: trond.kjeseth@sus.no.

Rolf E Hagen (RE)

Department of HPB Surgery, Oslo University Hospital, Rikshospitalet, Oslo, Norway.

Bjørn Edwin (B)

Department of HPB Surgery, Oslo University Hospital, Rikshospitalet, Oslo, Norway; The Intervention Centre, Oslo University Hospital, Oslo, Norway; Institute of Clinical Medicine, Medical Faculty, University of Oslo, Oslo, Norway.

Xiaoran Lai (X)

Oslo Centre for Biostatistics and Epidemiology, University of Oslo, Oslo, Norway.

Bård I Røsok (BI)

Department of HPB Surgery, Oslo University Hospital, Rikshospitalet, Oslo, Norway.

Tore Tholfsen (T)

Department of HPB Surgery, Oslo University Hospital, Rikshospitalet, Oslo, Norway.

Mushegh A Sahakyan (MA)

Department of HPB Surgery, Oslo University Hospital, Rikshospitalet, Oslo, Norway; The Intervention Centre, Oslo University Hospital, Oslo, Norway; Department of Surgery N1, Yerevan State Medical University after M. Heratsi, Yerevan, Armenia.

Dyre Kleive (D)

Department of HPB Surgery, Oslo University Hospital, Rikshospitalet, Oslo, Norway.

Classifications MeSH